Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory. The inserted DNA codes result in large quantities of recombinant protein produced through replication in living host cells.
Then we purify the recombinant protein and administer it to the animal (cat, dog, or horse) for targeted therapy. This final preparation (drug formulation) is sterile and contains a highly pure and targeted drug. One recombinant protein commonly used in human medicine is erythropoietin alpha (Epogen®).6